Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of October 2021
Date Filed: October 29, 2021
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet incorporating exhibits by reference rather than presenting a standalone financial statement.
Exhibits Submitted:
- Exhibit 99.1: Appendix 4C and Quarterly Cash Flow Report
Material Changes
The filing text does not contain specific details regarding material changes versus the prior comparable period. Investors must refer to the incorporated Exhibit 99.1 (Quarterly Cash Flow Report) for comparative financial data.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or disclosures of unusual items. The registrant is identified as a "development stage enterprise," which typically implies a focus on research and development rather than commercial revenue generation.
Investor Verification Checklist
- Review Exhibit 99.1 (Appendix 4C and Quarterly Cash Flow Report) for actual cash balance and burn rate data.
- Verify the company's status as a development stage enterprise and its current pipeline progress.
- Check the referenced Registration Statements (Form S-8 and Form F-3) for details on outstanding equity and potential dilution.
- Confirm the cash runway based on the quarterly cash flow report not included in this text summary.